Highlights BioArctic AB

Equities

BIOA B

SE0010323311

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm Other stock markets 09:30:00 10/04/2026 pm IST			5-day change	1st Jan Change
326.80 ^SEK	-0.24%		-0.18%	+5.15%

27/03	BioArctic proposes board expansion with new appointments	FW
27/03	Bioarctic AB Announces Declining of Re-Election by Pär Gellerfors as Board Member	CI

Highlights

23/03	Eisai Present New Data on Long-Term Real-World Treatment with Lecanemab	CI
23/03	BioArctic AB Partner Eisai Presents New Data on Lecanemab At 2026 AD/PDTM Congress	CI
20/03	Eisai Co Ltd And Biogen Inc Announce Real-World Long-Term Treatment Persistence With Leqembi	CI
20/03	Eisai Co., Ltd. And Biogen Inc. Present Real-World Data On Leqembi (Lecanemab-Irmb) Treatment Persistence In The United States	CI
18/02	Bioarctic AB Proposes Dividend for the Financial Year 2025	CI
18/02	BioArctic AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
18/02	Bioarctic proposes dividend of 2.00 SEK per share for 2025	RE
09/02	China Grants Priority Review to BioArctic's Subcutaneous Autoinjector to Treat Early Alzheimer's	MT
09/02	Bioarctic AB for Subcutaneous Formulation of Leqembi Designated for Priority Review in China	CI
06/02	Bioarctic reports Q4 sales of Leqembi at yen 20.7 billion	RE
27/01	BioArctic, Eisai Files Marketing Authorization Variation for Early Alzheimer's Disease Treatment in EU	MT
27/01	Eisai submits marketing authorisation variation to EMA	RE
27/01	Eisai Submits Marketing Authorisation Variation to EMA for Intraous Maintenance Dosing Every Four Weeks with Leqembi®?	CI
26/01	US FDA Places BioArctic Partner Eisai's Leqembi Iqlik Under Priority Review	MT
26/01	BioArctic says FDA grants priority review to Leqembi Iqlik supplemental application	RE
26/01	Eisai Co., Ltd. and Biogen Inc. Announces U.S. Food and Drug Administration Accepts Eisai Co., Ltd.'s Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Priority Review	CI
06/01	BioArctic's Leqembi Subcutaneous Formulation BLA Lands Acceptance in China	MT
09/12	BioArctic Partnership's Leqembi Makes China's Commercial Insurance Innovative Drug List	MT
09/12	Eisai Announces the Leqembi®? Included in China's Commercial Insurance Innovative Drug List	CI
28/11	BioArctic Seeks Japanese Approval for Subcutaneous Formulation of Alzheimer's Drug	MT
25/11	Global markets live: Amazon, Alphabet, Boeing, Novartis, Novo Nordisk…
25/11	Eisai Completes U.S. Rolling SBA Submission for Leqembi Iqlik e (Lecanemabirmb) as A Subcutaneous Starting Dose	CI
19/11	BioArctic AB's Partner Eisai to Present the Latest Findings on Lecanemab at the Clinical Trials on Alzheimer's Disease Conference	CI
14/11	Eisai Announces Leqembi Approval for IV Maintenance Treatment in the United Kingdom	CI
14/11	UK Approves BioArctic Partnership's Leqembi as IV Maintenance Treatment for Alzheimer's Disease	MT